About the journal
Seminars in Cancer Biology is a journal published by Elsevier BV in United States. It is listed in MEDLINE according to the sources read. Declared publication charge: 5,150 USD. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Elsevier BV
- ISSN
- 1044-579X · 1096-3650
- Country
- United States
- Access
- Not open access / not declared
- Declared publication charge
- 5,150 USD
- Declared peer-review model
- peer_review
- Official website
- https://www.journals.elsevier.com/seminars-in-cancer-biology
Index listings
- MEDLINE · 1990-01-01
- Indexing
- MEDLINE
- APC
- 5,150 USD
- Declared review time (DOAJ)
- —
- Actual review time (measured)
- 137 days received→accepted — computed from PubMed (n=75)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Works in OpenAlex
2673
Last recorded publication year
2026
h-index
227
i10-index
2178
From OpenAlex open data (CC0).
Editorial & policy4
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 79%
- ORCID iDs in current deposits
- 28%
- Deposits licence metadata at Crossref
- ✓
Identity & continuity3
- Alternate titles
- Cancer biology
- Source type
- journal
- NLM unique ID (PubMed)
- 9010218
Classification(no data)
No data available to the platform for this group
No platform data for: Classification — absence is not a judgment about the journal.
Subject areas
- Cancer Cells and Metastasis
- Cancer Cells and Metastasis
- Epigenetics and DNA Methylation
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Immunotherapy and Immune Responses
Show all subjects (50)
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Diverse Scientific and Economic Studies
- Diverse Scientific and Economic Studies
- Human auditory perception and evaluation
- Human auditory perception and evaluation
- Cancer-related Molecular Pathways
- Cancer-related Molecular Pathways
- Immune Cell Function and Interaction
- Immune Cell Function and Interaction
- MicroRNA in disease regulation
- MicroRNA in disease regulation
- Educational Robotics and Engineering
- Educational Robotics and Engineering
- Immune cells in cancer
- RNA modifications and cancer
- Immune cells in cancer
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Cancer-related molecular mechanisms research
- Lymphoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Ubiquitin and proteasome pathways
- Ubiquitin and proteasome pathways
- Viral-associated cancers and disorders
- Cancer Research and Treatments
- Cancer Research and Treatments
- Autophagy in Disease and Therapy
- Autophagy in Disease and Therapy
- Microtubule and mitosis dynamics
- Extracellular vesicles in disease
- Extracellular vesicles in disease
- Microtubule and mitosis dynamics
- Histone Deacetylase Inhibitors Research
- Histone Deacetylase Inhibitors Research
- CAR-T cell therapy research
- CAR-T cell therapy research
- RNA Interference and Gene Delivery
- RNA Interference and Gene Delivery
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ